AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

- 1. (Withdrawn) A method for preventing cancer comprising administering to a human or animal an effective amount of the growth factor vaccine composition of Claim 3.
- 2. (Withdrawn) The method of Claim 1, wherein the growth factor consists of SEQ ID NO: 10.
- 3. (Previously Presented) An immunogenic composition comprising an immunogenic peptide fragment, wherein the immunogenic peptide fragment comprises SEQ ID NO: 10.
 - 4. (Cancelled).
- 5. (Previously Presented) The composition of Claim 3, further comprising a pharmaceutically acceptable carrier.
- 6. (Previously Presented) The composition of Claim 5, wherein the pharmaceutically acceptable carrier comprises liposomes, vesicles, colloidal gold, or carrier proteins.
- 7. (Previously Presented) The composition of Claim 6, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole lympet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells or polymers of D and/or L-amino acids.

- 8. (Previously Presented) The composition of Claim 3, further comprising adjuvants, preservatives, diluents, emulsifiers, or stabilizers.
- 9. (Previously Presented) The composition of Claim 8, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, lipid A, Freund's incomplete adjuvant, Freund's complete adjuvant, polydispersed β-(1,4) linked acetylated mannan, polyoxyethylene-polyoxypropylene copolymer adjuvants, saponin derivative adjuvants, killed *Bordetella pertussis*, lipopolysaccharide of gram-negative bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and aluminum phosphate.
- 10. (Currently Amended) A composition for reducing hyperproliferative disorders comprising administering to a human or animal an effective amount of <u>an immunogenic</u> growth factor vaccine composition wherein the composition comprises SEQ ID NO: 10.
- 11. (Previously Presented) The composition of Claim 10, wherein the hyperproliferative disorder comprises hemangioma, solid tumors, blood borne tumors, leukemia, metastasis, telangiectasia, psoriasis, scleroderma, pyogenic granuloma, myocardial angiogenesis, Crohn's disease, plaque neovascularization, arteriovenous malformations, corneal diseases, rubeosis, neovascular glaucoma, diabetic retinopathy, retrolental fibroplasias, arthritis, diabetic neovascularizations, macular degeneration, wound healing, peptic ulcer, *Helicobacter* related diseases, fractures, keloids, vasculogenesis, hematopoiesis, ovulation, menstruation, placentation, or cat scratch fever.
- 12. (Currently Amended) A composition for reducing cancer comprising administering to a human or animal an effective amount of <u>an immunogenic</u> growth factor vaccine composition wherein the composition comprises SEQ ID NO: 10.
- 13. (Currently Amended) A composition for inhibiting tumor growth and metastasis comprising administering to a human or animal an effective amount of <u>an immunogenic</u> growth factor vaccine composition wherein the composition comprises SEQ ID NO: 10.